Details for Patent: 6,696,063

Title:	Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
Abstract:	Pathological regional adipose tissue accumulation associated with HIV-associated dysmorphic/dysmetabolic syndrome (HADDS) which may occur with or without subcutaneous adipose tissue lipodystrophy (and which is also described as HIV-associated adipose redistribution syndrome or HARS and other specific medical terms), is treated by administering an effective amount of human growth hormone or other substance which binds to and initiates signalling of the hGH receptor. Alternatively, a substance which stimulates production of endogenous hGH, such as human growth hormone releasing hormone, may be administered. HADDS and related syndromes include abnormal adipose tissue accumulation in the visceral, submandibular, supraclavicular, pectoral, mammary and/or dorsocervical (buffalo hump) area, and/or with subcutaneous lipomas, with or without associated metabolic or other physiologic abnormalities.
Inventor(s):	Torres; Ramon A. (New York, NY)
Assignee:	Applied Research Systems ARS Holding N.V. (Curacao, AN)
Filing Date:	Dec 30, 1999
Application Number:	09/475,989
Claims:	1. A method for treating HIV-associated dysmorphia/dysmetabolic syndrome (HADDS), comprising administering to a patient in need thereof an effective amount of a substance which is human growth hormone (hGH) or a functional derivative, fragment, variant, analog, or salt thereof which retains the biological activity of human growth hormone. 2. A method in accordance with claim 1, wherein said substance is an isolated human growth hormone. 3. The method according to claim 2, wherein said substance is recombinant human growth hormone. 4. The method according to claim 1, wherein said substance is administered subcutaneously. 5. The method according to claim 1, wherein said substance is administered intramuscularly. 6. The method according to claim 1, wherein said HADDS is abnormal visceral adipose tissue (VAT) accumulation and said patient is a HIV/AIDS patient presenting abnormal visceral adipose tissue accumulation. 7. The method according to claim 1, wherein said HADDS is dorsocervical adipose tissue accumulation ("buffalo hump") and said patient is a HIV/AIDS patient presenting dorsocervical adipose tissue accumulation ("buffalo hump"). 8. The method according to claim 1, wherein said HADDS is another type of pathological adipose accumulation associated with HADDS syndrome selected from the group consisting of abnormal accumulation of adipose tissue in submandibular ("horse collar"), supraclavicular, pectoral and/or mammary areas, and/or has lipomas (benign encapsulated fatty tumors, either single or multiple), and said patient is a HIV/AIDS patient presenting with one or more of these abnormal features. 9. A method in accordance with claim 1, wherein said substance is methionyl hGH. 10. A method in accordance with claim 1, wherein said substance is 20-K-hGH, a naturally-occurring variant of hGH found in the pituitary and in the bloodstream. 11. A method in accordance with claim 1, wherein said substance is GH-V, a naturally-occurring variant of hGH found in the placenta. 12. A method in accordance with claim 1, wherein said substance is two-chain anabolic protein (2-CAP) formed by controlled proteolysis of hGH with trypsin. 13. A method in accordance with claim 1, wherein said substance is deamidated hGH. 14. A method in accordance with claim 1, wherein said substance is sulfoxidated hGH. 15. A method in accordance with claim 1, wherein said substance is hGH acetylated at the N-terminus. 16. A method for treating the pathological accumulation of adipose tissue in specific regional depots, comprising administering to a patient in need thereof an effective amount of a substance which is human growth hormone or a functional derivative, fragment, variant, analog, or salt thereof which retains the biological activity of human growth hormone. 17. A method in accordance with claim 16, wherein said substance is an isolated human growth hormone. 18. The method according to claim 17, wherein said substance is recombinant human growth hormone. 19. The method according to claim 16, wherein said substance is administered subcutaneously. 20. The method according to claim 16, wherein said substance is administered intramuscularly. 21. A method in accordance with claim 16, wherein said substance is methionyl hGH. 22. A method in accordance with claim 16, wherein said substance is 20-K-hGH, a naturally-occurring variant of hGH found in the pituitary and in the bloodstream. 23. A method in accordance with claim 16, wherein said substance is GH-V, a naturally-occurring variant of hGH found in the placenta. 24. A method in accordance with claim 16, wherein said substance is two-chain anabolic protein (2-CAP) formed by controlled proteolysis of hGH with trypsin. 25. A method in accordance with claim 16, wherein said substance is deamidated hGH. 26. A method in accordance with claim 16, wherein said substance is sulfoxidated hGH. 27. A method in accordance with claim 16, wherein said substance is hGH acetylated at the N-terminus.